Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy

• Published in: JACC. Cardiovascular imaging 2017-09, Vol.10 (9), p.1031-1038
• Main Authors: Emami, Hamed, MD, Takx, Richard A.P., MD, PhD, Mayrhofer, Thomas, PhD, Janjua, Sumbal, MD, Park, Jakob, Pursnani, Amit, MD, Tawakol, Ahmed, MD, Lu, Michael T., MD, Ferencik, Maros, MD, PhD, Hoffmann, Udo, MD, MPH
• Format: Article
• Language: English
• Subjects: 2013 American College of Cardiology and American Heart Association prevention guidelines; African Americans; Aged; Cardiovascular; Clinical Decision-Making; Computed Tomography Angiography; Coronary Angiography - methods; coronary artery disease; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - drug therapy; Coronary Artery Disease - ethnology; Coronary Vessels - diagnostic imaging; Coronary Vessels - drug effects; European Continental Ancestry Group; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Prevalence; prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors
• ISSN: 1936-878X; 1876-7591
• DOI: 10.1016/j.jcmg.2016.10.022

Abstract Objectives This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA). Background Detection of nonobstructive CAD by coronary computed tomography angiography may improve risk stratification and permit individualized and more appropriate allocation of statin therapy. Methods This study determined the pooled hazard ratio of nonobstructive CAD for ASCVD events from published studies and incorporated this information into the ACC/AHA pooled cohort equation. The study calculated revised sex- and ethnicity-based 10-year ASCVD risk and determined boundaries corresponding to the original 7.5% risk for ASCVD events. It also assessed reclassification for statin eligibility by incorporating the results from meta-analysis to individual patients from a separate cohort. Results This study included 2 studies (2,295 subjects; 66% male; prevalence of nonobstructive CAD, 47%; median follow-up, 49 months; 67 ASCVD events). The hazard ratio of nonobstructive CAD for ASCVD events was 3.2 (95% confidence interval: 1.5 to 6.7). Incorporation of this information into the pooled cohort equation resulted in reclassification toward statin eligibility in individuals with nonobstructive CAD, with an original ASCVD score of 3.0% and 5.9% or higher in African-American women and men and a score of 4.4% and 4.6% or higher in Caucasian women and men, respectively. The absence of nonobstructive CAD resulted in reclassification toward statin ineligibility if the original ASCVD score was as 10.0% and 17.9% or lower in African-American women and men and 13.7% and 14.3% or lower in Caucasian women and men, respectively. Reclassification is observed in 14% of patients. Conclusions Detection of nonobstructive CAD by coronary computed tomography angiography improves risk stratification and permits individualized and more appropriate allocation of statin therapy across sex and ethnicity groups.